Specific fluorescence assay for advanced glycation end products in blood and urine of diabetic patients

Metabolism: Clinical and Experimental

Volumn 47, Issue 11, 1998, Pages 1348-1353

  Yanagisawa, Katsuyuki ^b   Makita, Zenji ^a   Shiroshita, Koichi ^b   Ueda, Toshihiro ^b   Fusegawa, Takashi ^b   Kuwajima, Satoru ^b   Takeuchi, Masayoshi ^b   Koike, Takao ^b  

^a HOKKAIDO UNIVERSITY   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CREATININE; HEMOGLOBIN A1C; PEPTIDE; UNCLASSIFIED DRUG;

ADULT; AGE; ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ANALYSIS; GLYCATION; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MICROALBUMINURIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL;

EID: 0031755717     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(98)90303-1     Document Type: Article

References (33)

1. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
2. Monnier VM, Kohn RR, Cerami A: Accelerated age-related browning of human collagen in diabetes mellitus. Proc Natl Acad Sci USA 82:583-587, 1984
3. Brownlee M, Cerami A, Vlassara H: Advanced glycosylation endproducts in tissue and the biochemical basis of diabetic complications. N Engl J Med 318:1315-1321, 1988
4. Monnier VM, Vishwanath V, Frank KF, et al: Relation between complications of type I diabetes mellitus and collagen-linked fluorescence. N Engl J Med 314:403-408, 1986
5. Vlassara H, Brownlee M, Cerami A: High-affinity-receptor mediated uptake and degradation of glucose-modified proteins: A potential mechanism for the removal of senescent macromolecules. Proc Natl Acad Sci USA 82:5588-5592, 1985
6. Radoff S, Vlassara H, Cerami A: Isolation of surface binding protein specific for advanced glycation end products from mouse macrophage-derived cell line RAW 264.7, Diabetes 39:1510-1518, 1990
7. Vlassara H, Bucala R, Striker LJ: Pathogenetic effects of advanced glycosylation; biochemical, biological, and clinical implications for diabetes and aging. Lab Invest 70:138-151, 1994
8. Makita Z, Radoff S, Rayfield EJ, et al: Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 325:836-841, 1991
9. Makita Z, Vlassara H, Cerami A, et al: Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 267:5133-5138, 1992
10. Makita Z, Bucala R, Rayfield EJ, et al: Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet 343:1519-1522, 1994
11. Papanastasiou P, Grass L, Rodela H, et al: Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or CAPD. Kidney Int 46:216-222, 1994
12. Dolhofer-Bliesener R, Lechner B, Deppisch R, et al: Immunological determination of advanced glycosylation end-products in human blood and urine. Nephrol Dial Transplant 10:657-664, 1995
13. Nakayama H, Taneda S, Kuwajima S, et al: Production and characterization of antibodies to advanced glycation products on proteins. Biochem Biophys Res Commun 162:740-745, 1989
14. Horiuchi S, Araki N, Morino Y: Immunochemical approach to characterize advanced glycation end products of the Maillard reaction. J Biol Chem 266:7329-7732, 1991
15. Mitsuhasshi T, Nakayama H, Itoh T, et al: Immunochemical detection of advanced glycation end products in renal cortex from STZ-induced diabetic rat. Diabetes 42:826-832, 1993
16. Igaki N, Sakai M, Hata H, et al : Effects of 3-deoxyglucosone on the Maillard reaction. Clin Chem 36:631-634, 1990
17. Nagarj R, Monnier VM: Non-tryptophan fluorescence and high molecular weight protein formation in lens crystallines of rats with chronic galactosemia: Prevention by the aldose reductase inhibitor sorbinil. Exp Eye Res 51:411-418, 1990
18. Lee WK, Akyol M, Shaw S, et ai: Kidney transplantation decrease the tissue level of advanced glycosylation end-products. Nephrol Dial Transplant 10:103-107, 1995
19. Gugliucci A, Bendayan M: Renal fate of circulation advanced glycated end products (AGE): Evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells. Diabetologia 39:149-160, 1996
20. Thome J, Munch G, Muller R, et al: Advanced glycation endproducts-associated parameters in the peripheral blood of patients with Alzheimer's disease. Life Sci 59:679-685, 1996
21. Makita Z, Vlassara H, Rayfield E, et al: Hemoglobin-AGE: A circulating marker of advanced glycation. Science 258:651-653, 1992
22. Bucala R, Makita Z, Koschinsky T, et al: Lipid advanced glycation. Pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA 90:6434-6438, 1993
23. Bucala R, Makita Z, Vega G, et al: Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 91:9441-9445, 1994
24. Bucala R, Model P, Cerami A: A modification of DNA by reducing sugars: A possible mechanism for nucleic acid aging and age-related dysfunction in gene expression. Proc Natl Acad Sci USA 81:105-109, 1984
25. Lee AT, Cerami A: Elevated glucose-6-phosphate levels are associated with plasmid mutations in vivo. Proc Natl Acad Sci USA 84:8311-8314, 1987
26. Zyzak DV, Richardson JM, Thorpe SR, et al: Formation of reactive intermediates from Amadori compounds under physiological conditions. Arch Biochem Biophys 316:547-554, 1995
27. Sell DR, Monnier VM: End-stage renal disease and diabetes catalyze the formation of a pentose-derived crosslink from aging human collagen. J Clin Invest 85:380-384, 1990
28. Taneda S, Monnier VM: ELISA of pentosidine, an advanced glycation end product, in biological specimens. Clin Chem 40:1766-1773, 1994
29. Odetti P, Fogarty J, Sell DR, et al: Chromatographic quantitation of plasma and erythrocyte pentosidine in diabetic and uremic subjects. Diabetes 41:153-159, 1992
30. Odetti P, Cosso L, Prozato MA, et al: Plasma advanced glycation end-products in maintenance hemodialysis patients. Nephrol Dial Transplant 10:2110-2113, 1995
31. Takahashi M, Ohishi T, Aoshima H, et al: The Maillard protein cross-link pentosidine in urine from diabetic patients. Diabetologia 36:664-667, 1993
32. Niwa T, Katsuzaki T, Momoi T, et al: Modification of β2m with advanced glycation end products as observed in dialysis-related amyloidosis by 3-DG accumulating in uremic serum. Kidney Int 49:861-867, 1996
33. Mitsuhashi T, Vlassara H, Li YM: Standardization of immunologiesl measurement for advanced glycation endproducts (AGEs) using normal human serum (NHS). Diabetes 45:220A, 1996 (suppl 2, abstr)